FIIs, FPIs barred in Fortis, Claris Lifesciences as overall limit crosses 24%, says RBI

Mumbai: The RBI on Wednesday said foreign buyers will not be able to buy any more shares in Fortis Healthcare and Claris Lifesciences as the prescribed limit has been reached.

The foreign institutional investors (FIIs)/foreign portfolio investors (FPIs) in Fortis Healthcare Ltd has crossed the overall limit of 24 percent of its paid-up capital, The Reserve Bank of India said.

Representational image. Reuters

Representational image. Reuters

"Therefore, no further purchases of shares of this company would be allowed through stock exchanges in India on behalf of Foreign institutional Investors (FIIs)/Foreign Portfolio Investors (FPIs)," it added.

In the case of Claris Lifesciences, RBI said holding by FIIs and FPIs too has crossed the overall limit of 24 percent. "Therefore, no further purchases of shares of this company (Claris) would be allowed through stock exchanges in India on behalf of FIIs/FPIs," RBI added.

FIIs, NRIs and PIOs (Persons of Indian Origins) can invest in primary and secondary capital markets in India through Portfolio Investment Scheme (PIS).

RBI monitors ceilings on FII/NRI/PIO investments in Indian companies on a daily basis. It has fixed the cut-off points two percentage points lower than the actual ceiling.


Updated Date: May 25, 2017 10:56 AM

Also Watch

Watch: The true stories from Dharavi that inspired Rajinikanth's Kaala
  • Thursday, March 8, 2018 Watch: Cyrus Khan talks about Parkour, jumping across walls and why he hates sitting
  • Thursday, May 31, 2018 Unwind: India's basketball sensation Amjyot Singh has his eyes set on becoming an NBA regular
  • Monday, May 28, 2018 First Day First Showsha — Review of Solo: A Star Wars Story in 10 questions
  • Saturday, May 19, 2018 Social Media Star: Rajkummar Rao and Bhuvan Bam open up about selfie culture, online trolls

Also See